Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9438 USD | +1.48% | +2.59% | +6.16% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 203.4 | 36.84 | 36.26 | 38.21 | - | - |
Enterprise Value (EV) 1 | 203.4 | 36.84 | 36.26 | 38.21 | 38.21 | 38.21 |
P/E ratio | -2.35 x | -0.49 x | -0.51 x | -0.95 x | -0.84 x | -0.34 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -3.34 x | -0.49 x | -0.51 x | -0.54 x | -0.39 x | - |
EV / FCF | -3.04 x | -0.55 x | -0.73 x | -0.61 x | -0.51 x | -0.38 x |
FCF Yield | -32.9% | -182% | -137% | -165% | -196% | -264% |
Price to Book | 0.5 x | - | - | - | - | - |
Nbr of stocks (in thousands) | 40,603 | 40,939 | 40,783 | 41,088 | - | - |
Reference price 2 | 5.010 | 0.9000 | 0.8890 | 0.9300 | 0.9300 | 0.9300 |
Announcement Date | 3/1/22 | 3/7/23 | 4/4/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA 1 | - | -60.91 | -74.69 | -70.54 | -70.69 | -98.23 | - |
EBIT 1 | -33.73 | -64.2 | -78.38 | -75.26 | -75.09 | -95.97 | -118.4 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -61.06 | -71.06 | -69.17 | -72.3 | -88 | -118.4 |
Net income 1 | -33.2 | -61.1 | -71.18 | -69.66 | -72.27 | -88 | -118.4 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | - | -2.130 | -1.820 | -1.740 | -0.9800 | -1.105 | -2.750 |
Free Cash Flow 1 | - | -66.92 | -67.05 | -49.55 | -63 | -75 | -101 |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 3/25/21 | 3/1/22 | 3/7/23 | 4/4/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | -11.38 | -13.7 | -24.52 | - |
EBIT 1 | -15.74 | -18.46 | -18.97 | -20.55 | -16.03 | -22.83 | -18.55 | -18.09 | -19.1 | -19.51 | -14.3 | -18.54 | -19.99 | -22.26 | -22 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -12.93 | -18.23 | -17.34 | -17.28 | -12.44 | -24.02 | -17.46 | -16.88 | -16.71 | -18.12 | -12.3 | -20 | -20 | -20 | -22 |
Net income 1 | -12.95 | -18.23 | -17.36 | -17.29 | -12.48 | -24.06 | -17.51 | -16.85 | -16.68 | -18.63 | -12.27 | -20 | -20 | -20 | -22 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.3400 | -0.4500 | -0.4500 | -0.4400 | -0.3200 | -0.6100 | -0.4400 | -0.4200 | -0.4200 | -0.4600 | -0.3000 | -0.4367 | -0.4567 | -0.3833 | -0.5300 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/9/21 | 3/1/22 | 5/10/22 | 8/9/22 | 11/8/22 | 3/7/23 | 5/10/23 | 8/4/23 | 11/13/23 | 4/4/24 | 5/8/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -66.9 | -67 | -49.5 | -63 | -75 | -101 |
ROE (net income / shareholders' equity) | - | -25.5% | -29.3% | -41.1% | -32.9% | - | - |
ROA (Net income/ Total Assets) | - | -22.8% | - | - | - | - | - |
Assets 1 | - | 268 | - | - | - | - | - |
Book Value Per Share | - | 10.10 | - | - | - | - | - |
Cash Flow per Share 2 | - | -2.070 | -1.520 | -1.210 | -0.1500 | -0.1000 | - |
Capex | - | 7.63 | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 3/25/21 | 3/1/22 | 3/7/23 | 4/4/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.16% | 38.21M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- ACHL Stock
- Financials Achilles Therapeutics plc